Oral oncology最新文献

英文中文

Comment on: Development and clinical implementation of a digital workflow utilizing 3D-printed oral stents for patients with head and neck cancer receiving radiotherapy 点评：利用3d打印口腔支架为接受放疗的头颈癌患者开发和临床实施数字工作流程。

IF 4 2区医学 Q1 DENTISTRY, ORAL SURGERY & MEDICINE

Oral oncology

Pub Date : 2025-02-01 DOI: 10.1016/j.oraloncology.2025.107195

Zi Yin, Huzi Zhao, Changqing Zhu, Juan Fang

引用次数: 0

Development of a prediction model for tube feeding dependence in HPV-associated oropharyngeal cancer patients undergoing chemoradiotherapy 人乳头瘤病毒相关口咽癌放化疗患者管饲依赖预测模型的建立。

IF 4 2区医学 Q1 DENTISTRY, ORAL SURGERY & MEDICINE

Oral oncology

Pub Date : 2025-02-01 DOI: 10.1016/j.oraloncology.2024.107132

Nicholas Dietrich , Erin Watson , Tony Tadic , Rosemary Martino , Scott Bratman , John Cho , John de Almeida , Lawson Eng , David Goldstein , Ezra Hahn , Andrew Hope , Ali Hosni , John Kim , Nauman Malik , Brian O’Sullivan , Enrique Sanz Garcia , Lillian Siu , Anna Spreafico , Susie Su , Jillian Tsai , Andrew J. McPartlin

Objectives

This study aimed to develop a prediction model for feeding tube dependence in a large homogenous cohort of HPV-associated oropharyngeal squamous cell carcinoma (HPV + OPSCC) patients receiving chemoradiotherapy (CRT). We further aimed to externally validate three previously published feeding tube prediction models on this cohort.

Materials and methods

p16-confirmed HPV + OPSCC patients treated with definitive CRT at a tertiary cancer centre between April 2017 and February 2022 were identified. The primary endpoint was G-tube dependence, defined as enteral feeding for ≥ 4 weeks following CRT. Clinical and dosimetric data were extracted from electronic patient records. Multivariable analyses (MVA) assessed the associations of potential predictors with G-tube dependence. The discriminatory performance of three previously published models was assessed on this cohort using the area under the receiver operating curve (AUC), and calibration was evaluated with calibration plots.

Results

A total of 291 patients were included (TNM8 stage I: 129; II:67; III: 95). MVA identified Dmean to the superior pharyngeal constrictor muscle, D70% to the middle pharyngeal constrictor muscle, and modified diet texture at baseline as predictive for G-tube dependence, with the AUC of 0.68. External validation of three existing models yielded an AUC of 0.60, 0.63, and 0.67, with no evidence of good calibration.

Conclusion

Despite a sizable cohort and comprehensive capture of dosimetric information, our prediction model, and external validation of previously published models, showed moderate performance. This suggests that additional factors beyond disease and treatment may need to be considered in future models to refine nutrition support decisions.

目的：本研究旨在建立一个大型同质队列HPV相关口咽鳞状细胞癌（HPV + OPSCC）接受放化疗（CRT）患者饲管依赖的预测模型。我们进一步的目的是在该队列中外部验证三个先前发表的饲管预测模型。材料和方法：2017年4月至2022年2月在三级癌症中心接受最终CRT治疗的p16确诊HPV + OPSCC患者。主要终点为g管依赖，定义为CRT后肠内喂养≥4周。临床和剂量学数据从电子病历中提取。多变量分析（MVA）评估了与g管依赖性相关的潜在预测因素。使用受试者工作曲线下面积（AUC）评估先前发表的三种模型在该队列中的歧视性表现，并使用校准图评估校准。结果：共纳入291例患者(TNM8 I期：129例；2: 67;第三:95)。MVA鉴定出对咽上收缩肌的Dmean，对咽中收缩肌的D70%，以及基线时改良的饮食质地可预测g管依赖，AUC为0.68。三种现有模型的外部验证得出的AUC分别为0.60、0.63和0.67，没有良好校准的证据。结论：尽管有相当大的队列和全面的剂量学信息捕获，我们的预测模型，以及先前发表的模型的外部验证，显示出中等的性能。这表明，在未来的模型中，可能需要考虑疾病和治疗之外的其他因素，以完善营养支持决策。

{"title":"Development of a prediction model for tube feeding dependence in HPV-associated oropharyngeal cancer patients undergoing chemoradiotherapy","authors":"Nicholas Dietrich , Erin Watson , Tony Tadic , Rosemary Martino , Scott Bratman , John Cho , John de Almeida , Lawson Eng , David Goldstein , Ezra Hahn , Andrew Hope , Ali Hosni , John Kim , Nauman Malik , Brian O’Sullivan , Enrique Sanz Garcia , Lillian Siu , Anna Spreafico , Susie Su , Jillian Tsai , Andrew J. McPartlin","doi":"10.1016/j.oraloncology.2024.107132","DOIUrl":"10.1016/j.oraloncology.2024.107132","url":null,"abstract":"<div><h3>Objectives</h3><div>This study aimed to develop a prediction model for feeding tube dependence in a large homogenous cohort of HPV-associated oropharyngeal squamous cell carcinoma (HPV + OPSCC) patients receiving chemoradiotherapy (CRT). We further aimed to externally validate three previously published feeding tube prediction models on this cohort.</div></div><div><h3>Materials and methods</h3><div>p16-confirmed HPV + OPSCC patients treated with definitive CRT at a tertiary cancer centre between April 2017 and February 2022 were identified. The primary endpoint was G-tube dependence, defined as enteral feeding for ≥ 4 weeks following CRT. Clinical and dosimetric data were extracted from electronic patient records. Multivariable analyses (MVA) assessed the associations of potential predictors with G-tube dependence. The discriminatory performance of three previously published models was assessed on this cohort using the area under the receiver operating curve (AUC), and calibration was evaluated with calibration plots.</div></div><div><h3>Results</h3><div>A total of 291 patients were included (TNM8 stage I: 129; II:67; III: 95). MVA identified Dmean to the superior pharyngeal constrictor muscle, D70% to the middle pharyngeal constrictor muscle, and modified diet texture at baseline as predictive for G-tube dependence, with the AUC of 0.68. External validation of three existing models yielded an AUC of 0.60, 0.63, and 0.67, with no evidence of good calibration.</div></div><div><h3>Conclusion</h3><div>Despite a sizable cohort and comprehensive capture of dosimetric information, our prediction model, and external validation of previously published models, showed moderate performance. This suggests that additional factors beyond disease and treatment may need to be considered in future models to refine nutrition support decisions.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"161 ","pages":"Article 107132"},"PeriodicalIF":4.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142896511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Progressive functional training in patients who underwent jaw defect reconstruction using vascularized iliac flaps: A randomized controlled trial 渐进式功能训练在使用带血管髂骨瓣重建颌骨缺损患者中的应用：一项随机对照试验。

IF 4 2区医学 Q1 DENTISTRY, ORAL SURGERY & MEDICINE

Oral oncology

Pub Date : 2025-02-01 DOI: 10.1016/j.oraloncology.2024.107150

Li Li , Li Wei , Jie Zhang, Jin-Chan Pu, Xiao-Ming Lv, Ming-Wei Huang

Objective

This trial was aimed at investigating the effects of progressive functional training on hip mobility, lower-limb stability, quality of life, and hip complications in patients who have undergone jaw defect reconstruction using vascularized iliac flaps.

Methods

Patients who underwent reconstruction surgery with vascularized iliac flaps were randomly divided into control and training groups. The control group, according to routine nursing practice, only received activity and safety guidance after the operation. The training group received progressive functional training for functional exercise. The primary outcomes were donor area function-Harris hip score and the timed “Up and Go” test. Secondary outcomes were patients’ quality of life, the hip visual analog scale, and other complications. Observations and evaluations were performed before the surgery and on postoperative day 7 and at months 1, 3, 6, and 12.

Results

The donor area function and quality of life of the patients in the training group were significantly improved at 1, 3, 6, and 12 months after surgery, and the differences were statistically significant. The load-dependent pain in the training group was significantly reduced compared with that in the control group. The incidence rates of gait disturbance at postoperative months 3, and 6 in the training group were significantly lower than the corresponding rates in the control group (P < 0.05).

Conclusion

Progressive functional training can accelerate the restoration of hip function and stability of lower-limb movement, alleviate gait disorders, relieve pain, and improve patients’ quality of life.

目的：本试验旨在探讨渐进式功能训练对使用带血管髂骨瓣进行颌骨缺损重建患者的髋关节活动能力、下肢稳定性、生活质量和髋关节并发症的影响。方法：将行带血管髂骨瓣重建手术的患者随机分为对照组和训练组。对照组按常规护理做法，术后仅接受活动及安全指导。训练组接受渐进式功能训练进行功能锻炼。主要结果是供体区域功能-哈里斯髋关节评分和定时“起跳”测试。次要结果是患者的生活质量、髋关节视觉模拟量表和其他并发症。术前、术后第7天以及第1、3、6和12个月进行观察和评估。结果：训练组患者术后1、3、6、12个月供区功能及生活质量均有明显改善，差异均有统计学意义。与对照组相比，训练组负荷依赖性疼痛明显减轻。训练组术后第3、6个月步态障碍发生率显著低于对照组（P < 0.05）。结论：渐进式功能训练可加速髋关节功能恢复和下肢运动稳定性，缓解步态障碍，减轻疼痛，提高患者生活质量。

{"title":"Progressive functional training in patients who underwent jaw defect reconstruction using vascularized iliac flaps: A randomized controlled trial","authors":"Li Li , Li Wei , Jie Zhang, Jin-Chan Pu, Xiao-Ming Lv, Ming-Wei Huang","doi":"10.1016/j.oraloncology.2024.107150","DOIUrl":"10.1016/j.oraloncology.2024.107150","url":null,"abstract":"<div><h3>Objective</h3><div>This trial was aimed at investigating the effects of progressive functional training on hip mobility, lower-limb stability, quality of life, and hip complications in patients who have undergone jaw defect reconstruction using vascularized iliac flaps.</div></div><div><h3>Methods</h3><div>Patients who underwent reconstruction surgery with vascularized iliac flaps were randomly divided into control and training groups. The control group, according to routine nursing practice, only received activity and safety guidance after the operation. The training group received progressive functional training for functional exercise. The primary outcomes were donor area function-Harris hip score and the timed “Up and Go” test. Secondary outcomes were patients’ quality of life, the hip visual analog scale, and other complications. Observations and evaluations were performed before the surgery and on postoperative day 7 and at months 1, 3, 6, and 12.</div></div><div><h3>Results</h3><div>The donor area function and quality of life of the patients in the training group were significantly improved at 1, 3, 6, and 12 months after surgery, and the differences were statistically significant. The load-dependent pain in the training group was significantly reduced compared with that in the control group. The incidence rates of gait disturbance at postoperative months 3, and 6 in the training group were significantly lower than the corresponding rates in the control group (<em>P</em> < 0.05).</div></div><div><h3>Conclusion</h3><div>Progressive functional training can accelerate the restoration of hip function and stability of lower-limb movement, alleviate gait disorders, relieve pain, and improve patients’ quality of life.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"161 ","pages":"Article 107150"},"PeriodicalIF":4.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142927529","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Reply to “Comment on Extensive necrosis of the tongue as a very early adverse event of head and neck radiotherapy“ 回复“关于头颈部放射治疗早期不良事件中舌头大面积坏死的评论”。

IF 4 2区医学 Q1 DENTISTRY, ORAL SURGERY & MEDICINE

Oral oncology

Pub Date : 2025-02-01 DOI: 10.1016/j.oraloncology.2025.107174

Valentina Zagardo, Stefano Pergolizzi, Gianluca Ferini

引用次数: 0

Pathologic responses and clinical outcomes with neoadjuvant doublet chemotherapy for newly diagnosed, surgically-resectable p16-positive oropharyngeal cancer 新诊断的可手术切除的p16阳性口咽癌新辅助双重化疗的病理反应和临床结果。

IF 4 2区医学 Q1 DENTISTRY, ORAL SURGERY & MEDICINE

Oral oncology

Pub Date : 2025-02-01 DOI: 10.1016/j.oraloncology.2024.107139

Alisha R. Pershad , Tatiana Ferraro , Timothy B. Shaver , Esther Lee , Leyn B. Shakhtour , Maxwell Madani , Punam G. Thakkar , Clint T. Allen , Shabnam Samankan , Faysal Haroun , Joseph F. Goodman , Arjun S. Joshi

Background

The feasibility and outcomes of neoadjuvant doublet chemotherapy with cisplatin and docetaxel followed by surgical resection of residual disease (NAC + S) for patients with newly diagnosed, resectable p16 positive (+) oropharyngeal squamous cell carcinoma (OPSCC) has been reported from a single institution. Here, we report pathologic responses, need for adjuvant treatment and recurrence-free survival (RFS) following this treatment from a second large academic institution.

Methods

A retrospective cohort study of patients with p16 + OPSCC receiving NAC + S and risk-adjusted adjuvant treatment between January 2017 and March 2024 was performed.

Results

Of the 76 patients who met the inclusion criteria, 43 (57%) patients developed clinical-to-pathologic downstaging; all remaining patients had clinical and pathologic stage I disease (AJCC 8th). Thirty-seven (49%) patients experienced complete pathologic response (pCR). Sixty-four (89%) patients avoided adjuvant treatment. Two-year overall survival (OS) and RFS were 93.7% and 75.4%, respectively. Development of a pCR did not statistically associate with improved RFS, but only 8 patients developed disease relapse. Of the 8 (11%) patients that recurred, 3 had developed a pCR and 5 had not.

Conclusions

Using risk-adjusted criteria from pathologic analysis, a high proportion of patients with newly diagnosed, resectable p16 + OPSCC appear to be able to avoid adjuvant treatment following the NAC + S treatment regimen without sacrificing disease control. Prospective clinical study of the NAC + S treatment strategy with clearly defined inclusion and adjuvant treatment criteria is warranted to determine whether this approach strategy can be safely offered to patients that wish to minimize the need for adjuvant radiation.

背景：已有一家机构报道了新诊断、可切除的p16阳性（+）口咽鳞状细胞癌（OPSCC）患者采用顺铂和多西他赛联合新辅助双重化疗后手术切除残留病变（NAC + S）的可行性和结果。在这里，我们报告病理反应，需要辅助治疗和无复发生存（RFS）后，从第二大学术机构的治疗。方法：对2017年1月至2024年3月期间接受NAC + S和风险调整辅助治疗的p16 + OPSCC患者进行回顾性队列研究。结果：在76例符合纳入标准的患者中，43例（57%）患者出现临床-病理降分期；其余患者均为临床和病理I期疾病（AJCC第8期）。37例（49%）患者出现完全病理反应（pCR）。64例（89%）患者避免了辅助治疗。2年总生存率（OS）和RFS分别为93.7%和75.4%。pCR的发展与RFS的改善没有统计学相关性，但只有8例患者出现疾病复发。在8例（11%）复发患者中，3例出现pCR， 5例没有。结论：根据病理分析的风险调整标准，高比例的新诊断可切除的p16 + OPSCC患者似乎能够避免NAC + S治疗方案后的辅助治疗，而不牺牲疾病控制。有必要对NAC + S治疗策略进行前瞻性临床研究，明确定义纳入和辅助治疗标准，以确定该方法策略是否可以安全地提供给希望减少辅助放疗需求的患者。

{"title":"Pathologic responses and clinical outcomes with neoadjuvant doublet chemotherapy for newly diagnosed, surgically-resectable p16-positive oropharyngeal cancer","authors":"Alisha R. Pershad , Tatiana Ferraro , Timothy B. Shaver , Esther Lee , Leyn B. Shakhtour , Maxwell Madani , Punam G. Thakkar , Clint T. Allen , Shabnam Samankan , Faysal Haroun , Joseph F. Goodman , Arjun S. Joshi","doi":"10.1016/j.oraloncology.2024.107139","DOIUrl":"10.1016/j.oraloncology.2024.107139","url":null,"abstract":"<div><h3>Background</h3><div>The feasibility and outcomes of neoadjuvant doublet chemotherapy with cisplatin and docetaxel followed by surgical resection of residual disease (NAC + S) for patients with newly diagnosed, resectable p16 positive (+) oropharyngeal squamous cell carcinoma (OPSCC) has been reported from a single institution. Here, we report pathologic responses, need for adjuvant treatment and recurrence-free survival (RFS) following this treatment from a second large academic institution.</div></div><div><h3>Methods</h3><div>A retrospective cohort study of patients with p16 + OPSCC receiving NAC + S and risk-adjusted adjuvant treatment between January 2017 and March 2024 was performed.</div></div><div><h3>Results</h3><div>Of the 76 patients who met the inclusion criteria, 43 (57%) patients developed clinical-to-pathologic downstaging; all remaining patients had clinical and pathologic stage I disease (AJCC 8th). Thirty-seven (49%) patients experienced complete pathologic response (pCR). Sixty-four (89%) patients avoided adjuvant treatment. Two-year overall survival (OS) and RFS were 93.7% and 75.4%, respectively. Development of a pCR did not statistically associate with improved RFS, but only 8 patients developed disease relapse. Of the 8 (11%) patients that recurred, 3 had developed a pCR and 5 had not.</div></div><div><h3>Conclusions</h3><div>Using risk-adjusted criteria from pathologic analysis, a high proportion of patients with newly diagnosed, resectable p16 + OPSCC appear to be able to avoid adjuvant treatment following the NAC + S treatment regimen without sacrificing disease control. Prospective clinical study of the NAC + S treatment strategy with clearly defined inclusion and adjuvant treatment criteria is warranted to determine whether this approach strategy can be safely offered to patients that wish to minimize the need for adjuvant radiation.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"161 ","pages":"Article 107139"},"PeriodicalIF":4.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142952716","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pain management following transoral robotic surgery for oropharyngeal squamous cell Carcinoma: A systematic review 经口机器人手术治疗口咽鳞状细胞癌后疼痛管理：系统综述。

IF 4 2区医学 Q1 DENTISTRY, ORAL SURGERY & MEDICINE

Oral oncology

Pub Date : 2025-02-01 DOI: 10.1016/j.oraloncology.2024.107147

George B. Sankar , Ghazal S. Daher , Lazaro R. Peraza , Eric J. Moore , Daniel L. Price , Kendall K. Tasche , Linda X. Yin , Toby N. Weingarten , Kathryn M. Van Abel

引用次数: 0

Association of race and ethnicity with quality of care among head and neck cancer patients in California 加利福尼亚州头颈部癌症患者的种族和民族与护理质量的关系。

IF 4 2区医学 Q1 DENTISTRY, ORAL SURGERY & MEDICINE

Oral oncology

Pub Date : 2025-02-01 DOI: 10.1016/j.oraloncology.2024.107144

Uchechukwu C. Megwalu, Yifei Ma, Vasu Divi

Background

There are significant racial disparities in head and neck cancer (HNC) outcomes. Racial differences in survival may be explained by differential access to high-quality care. The goal of this study was to evaluate the association of race and ethnicity with the quality of the treating hospital, and receipt of guideline-compliant care among HNC patients.

Methods

Retrospective cohort study of data from the California Cancer Registry dataset linked with discharge records and hospital characteristics. The study cohort included adult patients with HNC diagnosed between January 1, 2010, and December 31, 2019. Outcome measures included the quality of treating hospital, and NCCN guideline-compliant care.

Results

Black (OR 0.76, 95 % CI 0.67 to 0.85) and Hispanic (OR 0.68, 95 % CI 0.63 to 0.74) patients were less likely to be treated in top-quality hospitals compared with non-Hispanic White patients, after adjusting for demographic, and clinical factors. This association disappeared for Black patients, but persisted for Hispanic patients, after additionally adjusting for socioeconomic status and insurance status. Black patients with advanced-stage disease were less likely to be treated with dual-modality therapy (OR 0.82, 95 % CI 0.70 to 0.96), however, this association disappeared after adjusting for demographic, and clinical factors, and hospital quality.

Conclusion

There are significant racial and ethnic disparities in quality of care for patients with HNC. Our findings suggest that differential access to high-quality care may account for some of the racial disparities in HNC survival, and highlight the need for continued investigation into the drivers of racial disparities in HNC outcomes.

背景：头颈癌（HNC）预后存在显著的种族差异。种族间生存率的差异可以用获得高质量医疗服务的机会不同来解释。本研究的目的是评估种族和民族与治疗医院质量的关系，以及HNC患者接受指南依从性护理的情况。方法：回顾性队列研究来自加利福尼亚癌症登记数据集的数据，与出院记录和医院特征相关联。该研究队列包括2010年1月1日至2019年12月31日期间诊断为HNC的成年患者。结果测量包括治疗医院的质量和NCCN指南的依从性护理。结果：在调整了人口统计学和临床因素后，黑人（OR 0.76, 95% CI 0.67至0.85）和西班牙裔（OR 0.68, 95% CI 0.63至0.74）患者在高质量医院接受治疗的可能性低于非西班牙裔白人患者。这种关联在黑人患者中消失，但在西班牙裔患者中持续存在，在额外调整社会经济地位和保险状况后。患有晚期疾病的黑人患者不太可能接受双模式治疗（OR 0.82, 95% CI 0.70至0.96），然而，在调整了人口统计学、临床因素和医院质量后，这种关联消失了。结论：HNC患者的护理质量存在明显的种族差异。我们的研究结果表明，获得高质量护理的机会不同可能是HNC生存的一些种族差异的原因，并强调有必要继续研究HNC结局中种族差异的驱动因素。

{"title":"Association of race and ethnicity with quality of care among head and neck cancer patients in California","authors":"Uchechukwu C. Megwalu, Yifei Ma, Vasu Divi","doi":"10.1016/j.oraloncology.2024.107144","DOIUrl":"10.1016/j.oraloncology.2024.107144","url":null,"abstract":"<div><h3>Background</h3><div>There are significant racial disparities in head and neck cancer (HNC) outcomes. Racial differences in survival may be explained by differential access to high-quality care. The goal of this study was to evaluate the association of race and ethnicity with the quality of the treating hospital, and receipt of guideline-compliant care among HNC patients.</div></div><div><h3>Methods</h3><div>Retrospective cohort study of data from the California Cancer Registry dataset linked with discharge records and hospital characteristics. The study cohort included adult patients with HNC diagnosed between January 1, 2010, and December 31, 2019. Outcome measures included the quality of treating hospital, and NCCN guideline-compliant care.</div></div><div><h3>Results</h3><div>Black (OR 0.76, 95 % CI 0.67 to 0.85) and Hispanic (OR 0.68, 95 % CI 0.63 to 0.74) patients were less likely to be treated in top-quality hospitals compared with non-Hispanic White patients, after adjusting for demographic, and clinical factors. This association disappeared for Black patients, but persisted for Hispanic patients, after additionally adjusting for socioeconomic status and insurance status. Black patients with advanced-stage disease were less likely to be treated with dual-modality therapy (OR 0.82, 95 % CI 0.70 to 0.96), however, this association disappeared after adjusting for demographic, and clinical factors, and hospital quality.</div></div><div><h3>Conclusion</h3><div>There are significant racial and ethnic disparities in quality of care for patients with HNC. Our findings suggest that differential access to high-quality care may account for some of the racial disparities in HNC survival, and highlight the need for continued investigation into the drivers of racial disparities in HNC outcomes.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"161 ","pages":"Article 107144"},"PeriodicalIF":4.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142865069","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

IF 4 2区医学 Q1 DENTISTRY, ORAL SURGERY & MEDICINE

Oral oncology

Pub Date : 2025-02-01 DOI: 10.1016/j.oraloncology.2024.107161

Shihong Xu , Jiagang He , Zheran Liu , Yiyan Pei , Junyou Ge , Yan Qing , Youneng Wei , Ye Chen , Xingchen Peng

Background

Immune-related adverse events (irAEs) have been associated with better therapeutic outcomes in patients receiving immune checkpoint inhibitors (ICIs) across various cancers. This study investigates the association between irAEs and ICI outcomes in patients with recurrent or metastatic nasopharyngeal carcinoma (R/M NPC).

Methods

A post hoc analysis was performed on 153 patients with R/M NPC who received anti-PD-L1 inhibitors between February 26, 2019, and January 13, 2021. These patients were enrolled in a multicenter, single-arm, phase 2 clinical trial, which represents the largest study to date evaluating anti-PD-L1 therapy in previously treated R/M NPC.

Results

Patients who experienced irAEs had significantly higher overall response rates (ORR) and diseade control rates (DCR) compared to those without irAEs (31.2 % vs. 17.1 %, p = 0.039; 66.7 % vs. 44.8 %, p = 0.017). Additionally, the median progression-free survival (PFS) was longer in patients with irAEs (129 days vs. 56 days, p = 0.007). Patients with endocrine-related irAEs exhibited higher DCR (71.8 % vs. 46.2 %, p = 0.012), and longer PFS (144 days vs. 69 days, p = 0.02) and overall survival (OS: 746 days vs. 438 days, p = 0.02). In contrast, patients with grade ≥ 3 irAEs or those requiring systemic steroid therapy had shorter median OS (179 days vs. 466 days, p = 0.03; 166 days vs. 462 days, p = 0.02).

Conclusions

The occurrence of irAEs, particularly those involving the endocrine system, is associated with enhanced efficacy of anti-PD-L1 therapy and extended survival in patients with R/M NPC, highlighting their potential as prognostic biomarkers.

背景：在接受免疫检查点抑制剂（ICIs）治疗的各种癌症患者中，免疫相关不良事件（irAEs）与更好的治疗结果相关。本研究探讨了复发或转移性鼻咽癌（R/M鼻咽癌）患者irAEs与ICI预后之间的关系。方法：对2019年2月26日至2021年1月13日期间接受抗pd - l1抑制剂治疗的153例R/M NPC患者进行事后分析。这些患者被纳入了一项多中心、单臂、2期临床试验，这是迄今为止评估抗pd - l1治疗先前治疗过的R/M NPC的最大研究。结果：经历过irAEs的患者总体缓解率（ORR）和疾病控制率（DCR）明显高于未经历irAEs的患者(31.2% vs. 17.1%, p = 0.039；66.7% vs. 44.8%, p = 0.017)。此外，irAEs患者的中位无进展生存期（PFS）更长（129天比56天，p = 0.007）。内分泌相关irAEs患者表现出更高的DCR(71.8%对46.2%,p = 0.012)，更长的PFS（144天对69天，p = 0.02）和总生存期（OS: 746天对438天，p = 0.02）。相比之下，≥3级irae患者或需要全身性类固醇治疗的患者的中位生存期较短(179天vs 466天，p = 0.03；166天对462天，p = 0.02)。结论：irae的发生，特别是那些涉及内分泌系统的irae，与抗pd - l1治疗的疗效增强和R/M NPC患者生存期延长有关，突出了irae作为预后生物标志物的潜力。

{"title":"Immune-related adverse events as prognostic biomarkers in recurrent or metastatic nasopharyngeal carcinoma receiving PD-L1 inhibitor: A post-hoc analysis of the multicenter, single-arm, phase 2 study","authors":"Shihong Xu , Jiagang He , Zheran Liu , Yiyan Pei , Junyou Ge , Yan Qing , Youneng Wei , Ye Chen , Xingchen Peng","doi":"10.1016/j.oraloncology.2024.107161","DOIUrl":"10.1016/j.oraloncology.2024.107161","url":null,"abstract":"<div><h3>Background</h3><div>Immune-related adverse events (irAEs) have been associated with better therapeutic outcomes in patients receiving immune checkpoint inhibitors (ICIs) across various cancers. This study investigates the association between irAEs and ICI outcomes in patients with recurrent or metastatic nasopharyngeal carcinoma (R/M NPC).</div></div><div><h3>Methods</h3><div>A post hoc analysis was performed on 153 patients with R/M NPC who received anti-PD-L1 inhibitors between February 26, 2019, and January 13, 2021. These patients were enrolled in a multicenter, single-arm, phase 2 clinical trial, which represents the largest study to date evaluating anti-PD-L1 therapy in previously treated R/M NPC.</div></div><div><h3>Results</h3><div>Patients who experienced irAEs had significantly higher overall response rates (ORR) and diseade control rates (DCR) compared to those without irAEs (31.2 % vs. 17.1 %, p = 0.039; 66.7 % vs. 44.8 %, p = 0.017). Additionally, the median progression-free survival (PFS) was longer in patients with irAEs (129 days vs. 56 days, p = 0.007). Patients with endocrine-related irAEs exhibited higher DCR (71.8 % vs. 46.2 %, p = 0.012), and longer PFS (144 days vs. 69 days, p = 0.02) and overall survival (OS: 746 days vs. 438 days, p = 0.02). In contrast, patients with grade ≥ 3 irAEs or thoserequiring systemic steroid therapy had shorter median OS (179 days vs. 466 days, p = 0.03; 166 days vs. 462 days, p = 0.02).</div></div><div><h3>Conclusions</h3><div>The occurrence of irAEs, particularly those involving the endocrine system, is associated with enhanced efficacy of anti-PD-L1 therapy and extended survival in patients with R/M NPC, highlighting their potential as prognostic biomarkers.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"161 ","pages":"Article 107161"},"PeriodicalIF":4.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142922334","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Commentary on “Induction chemotherapy for locally advanced nasopharyngeal carcinoma: Efficacy and safety of the TPC regimen compared to GP and TPF” 对“局部晚期鼻咽癌诱导化疗：TPC方案与GP和TPF方案的疗效和安全性”的评论。

IF 4 2区医学 Q1 DENTISTRY, ORAL SURGERY & MEDICINE

Oral oncology

Pub Date : 2025-02-01 DOI: 10.1016/j.oraloncology.2025.107175

Erkan Topkan , Efsun Somay , Ugur Selek

引用次数: 0

Prognostic significance of diagnosis-to-surgery interval in oral cavity squamous cell carcinoma: A nationwide study

IF 4 2区医学 Q1 DENTISTRY, ORAL SURGERY & MEDICINE

Oral oncology

Pub Date : 2025-02-01 DOI: 10.1016/j.oraloncology.2025.107196

Chung-Jan Kang , Yu-Wen Wen , Chien-Yu Lin , Shu-Hang Ng , Yao-Te Tsai , Hsiu-Ying Ku , Pei-Jen Lou , Cheng Ping Wang , Jin-Ching Lin , Chun-Hung Hua , Shu-Ru Lee , Kang-Hsing Fan , Wen-Cheng Chen , Li-Yu Lee , Chih-Yen Chien , Tsung-Ming Chen , Shyuang-Der Terng , Chi-Ying Tsai , Hung-Ming Wang , Chia-Hsun Hsieh , Chun-Ta Liao

Background

The question as to whether prolonged diagnosis-to-surgery intervals (DSIs) may compromise survival outcomes in patients with oral cavity squamous cell carcinoma (OCSCC) remains unanswered. This nationwide study was designed to address this issue.

Methods

We analyzed data from 26,214 patients with first primary OCSCC identified in the Taiwanese Cancer Registry Database between 2011 and 2021. The optimal DSI cutoff was determined based on 5-year disease-specific survival (DSS) and overall survival (OS) rates using Cox regression analysis. Patients were categorized into three distinct DSI groups: ≤20 days (47 %), 21–31 days (31 %), and > 31 days (22 %).

Results

The 5-year DSS and OS rates for the ≤20/21–31/>31 days groups were 81 %/78 %/77 % and 73 %/70 %/68 %, respectively (both p < 0.0001). Patients in the ≤20 days group had a higher prevalence of pathological stages I–II. After adjustment for potential confounders in multivariable analysis, a DSI > 31 days (versus ≤ 20 days) retained independent associations with adverse outcomes at 5 years, with hazard ratios of 1.07 for both DSS and OS. Propensity score matching and multivariable analysis comparing DSI ≤ 20 days to DSI > 31 days stratified by pathological stage III–IV showed that higher DSS and OS rates were observed in patients with DSI ≤ 20 days than DSI > 31 days (68 %/66 %, p = 0.0586; 60 %/57 %, p = 0.0228, respectively), with hazard ratios of 1.09 for both DSS and OS.

Conclusions

Our findings indicate that DSI is an independent predictor of 5-year DSS and OS in patients with OCSCC. A DSI exceeding 31 days, or even 21 days, may potentially decrease survival outcomes.

{"title":"Prognostic significance of diagnosis-to-surgery interval in oral cavity squamous cell carcinoma: A nationwide study","authors":"Chung-Jan Kang , Yu-Wen Wen , Chien-Yu Lin , Shu-Hang Ng , Yao-Te Tsai , Hsiu-Ying Ku , Pei-Jen Lou , Cheng Ping Wang , Jin-Ching Lin , Chun-Hung Hua , Shu-Ru Lee , Kang-Hsing Fan , Wen-Cheng Chen , Li-Yu Lee , Chih-Yen Chien , Tsung-Ming Chen , Shyuang-Der Terng , Chi-Ying Tsai , Hung-Ming Wang , Chia-Hsun Hsieh , Chun-Ta Liao","doi":"10.1016/j.oraloncology.2025.107196","DOIUrl":"10.1016/j.oraloncology.2025.107196","url":null,"abstract":"<div><h3>Background</h3><div>The question as to whether prolonged diagnosis-to-surgery intervals (DSIs) may compromise survival outcomes in patients with oral cavity squamous cell carcinoma (OCSCC) remains unanswered. This nationwide study was designed to address this issue.</div></div><div><h3>Methods</h3><div>We analyzed data from 26,214 patients with first primary OCSCC identified in the Taiwanese Cancer Registry Database between 2011 and 2021. The optimal DSI cutoff was determined based on 5-year disease-specific survival (DSS) and overall survival (OS) rates using Cox regression analysis. Patients were categorized into three distinct DSI groups: ≤20 days (47 %), 21–31 days (31 %), and > 31 days (22 %).</div></div><div><h3>Results</h3><div>The 5-year DSS and OS rates for the ≤20/21–31/>31 days groups were 81 %/78 %/77 % and 73 %/70 %/68 %, respectively (both <em>p</em> < 0.0001). Patients in the ≤20 days group had a higher prevalence of pathological stages I–II. After adjustment for potential confounders in multivariable analysis, a DSI > 31 days (<em>versus</em> ≤ 20 days) retained independent associations with adverse outcomes at 5 years, with hazard ratios of 1.07 for both DSS and OS. Propensity score matching and multivariable analysis comparing DSI ≤ 20 days to DSI > 31 days stratified by pathological stage III–IV showed that higher DSS and OS rates were observed in patients with DSI ≤ 20 days than DSI > 31 days (68 %<em>/</em>66 %, <em>p</em> = 0.0586; 60 %<em>/</em>57 %, <em>p</em> = 0.0228, respectively), with hazard ratios of 1.09 for both DSS and OS.</div></div><div><h3>Conclusions</h3><div>Our findings indicate that DSI is an independent predictor of 5-year DSS and OS in patients with OCSCC. A DSI exceeding 31 days, or even 21 days, may potentially decrease survival outcomes.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"161 ","pages":"Article 107196"},"PeriodicalIF":4.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143024220","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Oral oncology

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀